In high-volume oral solid dose manufacturing, ferrous gluconate dihydrate is processed by wet granulation rather than direct compression because the API has a needle-like crystal habit that promotes die flow variability and lamination when compressed at turret speeds above 30 rpm. A representative iron supplement tablet uses 300 mg ferrous gluconate dihydrate in a 600 mg core, corresponding to an API addition ratio of 50.0 wt% and delivering 34.8 mg elemental iron per tablet when the API contains 11.6% Fe on dried basis. The core formulation is completed with microcrystalline cellulose 32.0 wt%, crospovidone 4.0 wt%, povidone K30 3.0 wt% as aqueous binder, and magnesium stearate 0.75 wt%. Wet granulation is performed in a high-shear granulator at an impeller speed of 150–200 rpm and chopper speed of 1500–2000 rpm; purified water containing dissolved povidone is added at 10–15 g/min until granule endpoint is reached. The wet mass is passed through a 1.5 mm screen and dried in a fluid-bed dryer at inlet air temperature 55–60°C to a loss on drying of 1.5–2.0%. Dried granules are milled through a 0.8 mm conical mill, then blended with extragranular crospovidone and magnesium stearate for no more than 5 min at 20 rpm to avoid hydrophobic film formation. Compression on a rotary tablet press operates at 8–14 kN main compression force, producing tablets with hardness 70–100 N and friability below 0.5% as determined by USP 1216. Aqueous film coating is applied in a side-vented coating pan at bed temperature 38–42°C, pan speed 8–12 rpm, and coating weight gain 2.5–3.0%; the coating step reduces surface oxidation and masks metallic taste. Release testing includes USP 711 dissolution in 0.1 N HCl, 900 mL, paddle 50 rpm, with product-specific Q commonly not less than 75% at 45 min, USP 701 disintegration, USP 905 content uniformity, and ICH Q3D Table A.1.1 oral PDE elemental impurity limits. The terminal finished product types are film-coated or sugar-coated oral tablets labeled as 240 mg or 300 mg ferrous gluconate dihydrate, filled into HDPE bottles with desiccant canisters or cold-form foil blisters.

What Physical Properties Constrain Capsule Fill Weight and Plug Integrity in Ferrous Gluconate Formulation?

Capsule filling of ferrous gluconate dihydrate demands particle size enlargement and flow conditioning because the raw API typically exhibits bulk density below 0.5 g/cm³ and angle of repose above 40°, values that cause static adhesion and weight variation on automatic capsule machines. Dry granulation by roller compaction is used when moisture exposure from wet granulation would darken the gluconate surface and produce sticky granule agglomerates. A representative hard capsule formulation contains 300 mg ferrous gluconate dihydrate in a fill mass of 520 mg, equal to 57.7 wt% API; the remainder consists of microcrystalline cellulose 34.0 wt%, sodium starch glycolate 5.0 wt%, colloidal silicon dioxide 0.8 wt%, and magnesium stearate 0.5 wt%. Roller compaction is performed at roll force 8–12 kN/cm, roll speed 4–8 rpm, and granule screen size 1.0 mm; the resulting ribbon is milled to yield granules with tapped bulk density 0.65–0.75 g/mL and Carr index below 20%. Capsule filling on a dosator-type machine uses size 0 hard gelatin or hypromellose capsules at filling speeds of 30,000–80,000 capsules/h with weight variation controlled to ± 3% around target. In-process testing measures plug compression force and closure length; fill weight rejection limits are set by USP 905 content uniformity and USP 711 dissolution. Dissolution uses 0.1 N HCl at 37 ± 0.5°C, 900 mL volume, and paddle rotation 50 rpm; Q values are product-specific and commonly not less than 75% at 45 min. Terminal dosage forms are hard gelatin capsules or HPMC capsules containing 240 mg or 300 mg ferrous gluconate dihydrate, often packaged in PVC/PVDC or Aclar blisters with desiccant if the capsule is gelatin-based and ambient RH exceeds 60%.

Fluid-bed granulation converts ferrous gluconate into a dispersible oral granule that meets 180 µm sieve retention limits and dissolves without a sugar carrier

Ferrous gluconate sachet granulation is not a direct substitution of tablet granule because the finished granule must disperse in water within 30 s at 25°C and must not form a floating metallic film. The addition ratio in single-dose stick packs is lower than in tablets: a 2.0 g sachet contains 300 mg ferrous gluconate dihydrate, an API load of 15.0 wt%, to leave sufficient mass for sweeteners, acidifiers, and dispersion aids. A representative granule blend comprises ferrous gluconate dihydrate 15.0 wt%, sorbitol 65.0 wt%, pregelatinized starch 12.0 wt%, citric acid monohydrate 5.0 wt%, ascorbic acid 2.0 wt%, and silicon dioxide 1.0 wt%. Fluid-bed top-spray granulation is selected because high-shear granulation produces dense granules with poor water penetration. The binder solution contains povidone K30 at 4.0 wt% in water and is sprayed at 12–18 g/min over a 25 kg batch; inlet air temperature is 55–65°C, product temperature 32–38°C, and atomization pressure 1.5–2.0 bar. Dried granules are sieved through 1.0 mm and 180 µm screens to remove oversized agglomerates and fines; target LOD is 1.2–1.8%. Stick-pack filling on vertical form-fill-seal machines operates with nitrogen flushing to keep headspace oxygen below 3% and seal integrity checked by vacuum decay at −0.8 bar. Release includes USP 711 dissolution of the reconstituted suspension, water activity below 0.60, USP-NF monograph compliance for ferrous gluconate, and ICH Q3D elemental impurity control. Finished products are single-dose sachets or stick packs labeled as 300 mg ferrous gluconate per 2.0 g granule, intended for adults and elderly patients who cannot swallow tablets.

Ferrous gluconate dihydrate dissolves in purified water with gentle heating, and a common oral syrup delivers 300 mg ferrous gluconate per 5 mL dose, equivalent to a concentration of 6.0% w/v API and 34.8 mg elemental iron per 5 mL. The solution is thermodynamically unstable because dissolved Fe²⁺ oxidizes to Fe³⁺ in the presence of dissolved oxygen, and visible brown precipitates form above pH 4.5; therefore the manufacturing process uses a citric acid buffer to hold pH between 3.8 and 4.2, nitrogen sparging to maintain dissolved oxygen below 0.5 mg/L, and ascorbic acid 0.2% w/v as an oxygen scavenger. In production, purified water is charged into a 316L stainless steel vessel and sparged with nitrogen for 15 min; ferrous gluconate is added under gentle agitation at 35–40°C, followed by sucrose 45% w/v, sodium benzoate 0.1% w/v, and disodium edetate 0.01% w/v to chelate trace metal ions that catalyze oxidation. The batch is cooled to 25°C, pH-adjusted, and clarified through a 0.45 µm filter cartridge before filling. Filling into amber Type III glass bottles under nitrogen overlay limits photodegradation; closures are child-resistant polypropylene caps with induction-sealed liners. Release testing follows USP 711 dissolution for oral solutions where applicable, USP 660 glass container testing, ICH Q1A(R2) photostability, and 21 CFR 210 and 211 cGMP. Finished product types are oral syrup, pediatric oral drops, and unit-dose drinkable ampoules with elemental iron content calculated from the 11.6% Fe content of the API.

When Ferrous Gluconate Is Specified for Parenteral Use, Fe²⁺ Speciation, pH, and Particulate Burden Determine Feasibility

Injectable-grade ferrous gluconate dihydrate is not equivalent to oral-grade material, and uncomplexed Fe²⁺ salts are not the pharmacopeial injectable iron products; published data for direct intravenous administration of ferrous gluconate without complexation is limited. Fe²⁺ oxidizes rapidly at pH above 6.0 to Fe³⁺, forming sparingly soluble iron hydroxide colloids that increase particulate load and venous irritation. If a parenteral formulation is prepared for compatibility screening or as a manufacturing intermediate, ferrous gluconate dihydrate is dissolved at 0.05–0.1% w/v in nitrogen-sparged 0.9% sodium chloride injection, giving 0.5–1.0 mg/mL ferrous gluconate and 58–116 µg/mL elemental iron; sodium citrate is used to maintain pH 3.5–4.0 and to provide weak complexation. The addition ratio is intentionally low because higher concentrations exceed the solubility product of ferrous hydroxide at the pH shift that occurs upon dilution into blood and because the injectable dosage form must remain clear in USP 788 particulate matter testing. Aseptic manufacturing is required: the solution is prepared in a Grade C area using Water for Injection, filtered through a 0.22 µm PVDF membrane, filled into Type I borosilicate glass vials under Grade A, and terminally autoclaved only if formulation stability data supports it; if autoclaving is not possible, aseptic filtration is the sole sterilization step. In-process controls include dissolved oxygen below 0.5 mg/L, limit of bacterial endotoxins by USP 85, sterility by USP 71, particulate matter by USP 788, and extractables from the rubber closure per USP 381. Terminal finished product types are limited to investigational injectable solutions or intermediates for ferric-gluconate complex manufacture; no USP monograph for a ferrous gluconate injection exists, so any commercial use must be supported by a regulatory dossier demonstrating safety and stability.

Antioxidant Excipient Interactions in Prenatal Multivitamin-Mineral Tablets Using Ferrous Gluconate

In prenatal multivitamin-mineral formulations, ferrous gluconate is selected because it delivers a lower free-iron burden in the gastrointestinal lumen than ferrous sulfate and has a less astringent taste in chewable or coated tablets. The addition ratio is constrained by the high mass of other vitamins and minerals: a prenatal tablet with 27 mg elemental iron as ferrous gluconate requires 233 mg ferrous gluconate dihydrate; in a 1250 mg tablet core, this equals 18.6 wt% API. Manufacturing uses separate granulation streams to prevent direct contact between Fe²⁺ and oxygen-sensitive vitamins. The iron granule is produced by wet granulation with povidone K30 3.0 wt%, microcrystalline cellulose 25.0 wt%, and ascorbic acid 60 mg per tablet as an absorption enhancer; the vitamin granule contains thiamine, riboflavin, folic acid, and vitamin D3, with the vitamin D3 component protected from moisture by a dry blend with calcium phosphate. The two granule fractions are blended in a low-shear bin blender for 10 min at 12 rpm, then lubricated with magnesium stearate 0.8 wt% for 3–5 min. Compression uses a rotary press with 20–25 kN force due to the large tablet diameter and the brittle calcium phosphate excipient; tablet hardness is controlled at 90–140 N to maintain disintegration. If a bilayer press is used, the iron-containing layer is compressed at 8–10 kN precompression and 15–18 kN main compression, while the vitamin layer is compressed at 10–12 kN to reduce delamination at the interface. Aqueous film coating at 3.0–4.0% weight gain provides a moisture barrier; the coating pan relative humidity is kept below 45% to avoid darkening of the iron granule. Release testing includes USP 711 dissolution for iron, USP 701 disintegration, USP 905 content uniformity for folic acid and iron, and ICH Q3D elemental impurities. Finished products are film-coated prenatal multivitamin-mineral tablets, chewable prenatal tablets, and coated caplets labeled with 27 mg elemental iron from ferrous gluconate and packaged in cold-form aluminum blisters to limit oxidation.